BUILDING A NEW KIND OF BIOPHARMA COMPANY
From the beginning, our team of scientists, engineers, drug developers and senior leaders in pharma set out to build a new type of biopharma company, one founded on our shared passion for saving lives.
We apply our collective and deep industry knowledge to address unmet needs for cancer and neurological disease treatments. We believe in the power of using molecular data to understand the biology of disease. Together we are building a new kind of biopharma company – one that will address the needs of many to save more lives and improve health.
Our team has developed and commercialized novel drugs, diagnostics, and deep analytics software.
Pek Lum, PhD
Pek Lum has more than 20 years of genomics and drug discovery experience. She is the chief architect of the science behind Auransa’s technology, combining her deep understanding of genomics and her vast experience in applying data science in the pharmaceutical industry.
Before founding Auransa, Pek was an early employee and vice president of Product and chief data scientist for Ayasdi, where she created early business verticals and helped grow the company from a few people to several dozen employees. Pek started off her career at Rosetta Inpharmatics, a pioneer in genomics and microarray technology. When Rosetta was acquired by Merck, Pek continued to champion the integration of data science into traditional biology, contributing to Merck’s development pipeline. While at Merck, Pek held roles of increasing responsibility, including leading molecular profiling for the diabetes, cardiovascular and obesity franchises. Pek received her Ph.D. in yeast genetics at the University of Washington, Seattle. Her work has been widely published in scientific and medical journals, such as Nature and Cell, and her research has contributed to discoveries in drug development and the understanding of complex diseases. She has previously served as an advisor to the Michael J. Fox Foundation for Parkinson’s Research and Resolution Bioscience, and is currently an advisor for Sequence Bio and Bayes Impact.
Viwat Visuthikraisee, PhD
Viwat Visuthikraisee has more than 20 years of experience in software engineering, algorithm development and operations management. He oversees all aspects of operations at Auransa.
Viwat is a physicist turned entrepreneur. Before founding Auransa, he was a consulting operations manager and software architect specializing in supply chain logistics. He spent his early career at RAF Technology Inc., a computer vision and intelligent software company, where he learned to appreciate software design, algorithm development and building specialized databases for intelligent applications. Winning the prestigious Japanese Monbusho Scholarship, Viwat studied in Japan and received his B.S. and M.S. in Applied Physics from Hokkaido University and his Ph.D. in Theoretical Physics at the University of Washington, Seattle.
Andy Protter, PhD
Andy Protter has more than 35 years of pharmaceutical industry experience working on preclinical research and development projects involving proteins, peptides and small molecules. At Auransa, he is responsible for all research, discovery and preclinical development activities.
Before joining Auransa, Andy held various R&D and business development leadership roles at Medivation and Scios Inc. (acquired by Johnson & Johnson), where he won the Johnson Medal for his work on Natrecor, a product approved for decompensated congestive heart failure. While at Medivation, Andy was responsible for preclinical pharmacology and toxicology of Enzalutamide, a drug approved for advanced prostate cancer, and he participated in the in-licensing of the phase III PARPx inhibitor Talazoparib. He also led the first successful cloning of apoB, the primary protein on LDL, and has participated in work described in more than 84 published papers, four book chapters and 28 patents. Andy earned a Ph.D. in Biochemistry from the State University of New York at Stony Brook.
Greg Luedtke, PhD
Greg earned his PhD in organic chemistry from Montana State University and completed a post-doctoral fellowship at Stanford University. His industrial career includes more than ten years at Scios Inc., where he was the research team leader for the company’s p38 kinase inhibitor program, advancing two molecules into clinical trials. Greg’s interests include efficiently managing virtual resources to bring about successful drug discovery outcomes. When not working, he spends time with his Belgian Malinois.